Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain

PHASE3CompletedINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

March 31, 2010

Study Completion Date

May 31, 2010

Conditions
Alzheimer's Disease
Interventions
DRUG

florbetapir F 18

Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration

Trial Locations (25)

11040

Research Site, New Hyde Park

12208

Research Site, Albany

21221

Research Site, Baltimore

27710

Research Site, Durham

29425

Research Site, Charleston

32835

Research Site, Orlando

33137

Research Site, Miami

33140

Research Site, Miami Beach

33166

Research Site, Miami Springs

33407

Research Site, West Palm Beach

33709

Research Site, St. Petersburg

33912

Research Site, Fort Myers

34231

Research Site, Sarasota

37614

Research Site, Johnson City

39401

Research Site, Hattiesburg

45459

Research Site, Centerville

63141

Research Site, St Louis

72211

Research Site, Little Rock

73112

Research Site, Oklahoma City

85006

Research Site, Phoenix

85258

Research Site, Scottsdale

85351

Research Site, Sun City

92697

Research Site, Irvine

94109

Research Site, San Francisco

05201

Research Site, Bennington

Sponsors
All Listed Sponsors
lead

Avid Radiopharmaceuticals

INDUSTRY